What's Happening?
Niowave has commenced the construction of a $75 million facility in Lansing, Michigan, aimed at increasing its production capacity for the radioisotope actinium-225. This development follows Niowave's recent agreements with pharmaceutical giants AstraZeneca
and Novartis to supply the isotope, which is crucial for developing next-generation radiopharmaceuticals. The new facility will feature multiple proprietary superconducting linear accelerators and is expected to be operational by 2028, creating approximately 70 jobs in research and development, engineering, and quality assurance. Historically, the demand for actinium-225 was met by Oak Ridge National Laboratory through the decay of thorium-229. However, the growing interest in actinium-225 for drug development has led to increased investments in its production capacity.
Why It's Important?
The construction of Niowave's new facility is a significant step in addressing the global demand for actinium-225, a radioisotope with potential applications in cancer treatment. The isotope's ability to emit high energy over a small area makes it a promising candidate for targeted radiopharmaceuticals, differentiating it from other isotopes like lutetium-177. The expansion of production capabilities is crucial as shortages of actinium-225 have previously impacted clinical trials, such as Bristol Myers Squibb's RayzeBio Phase 3 trial in 2024. By increasing the supply of this isotope, Niowave and its partners aim to support the development of innovative cancer therapies, potentially benefiting patients and advancing the pharmaceutical industry.
What's Next?
As Niowave progresses with the construction of its new facility, the company is poised to play a pivotal role in the supply chain for actinium-225. The facility's completion in 2028 will likely enhance Niowave's ability to meet the growing demand from pharmaceutical companies investing in actinium-225-based therapies. Additionally, other companies like Cardinal Health and TerraPower Isotopes are also expanding their production capabilities, indicating a broader industry trend towards securing reliable sources of this critical isotope. The increased availability of actinium-225 could accelerate the development and approval of new radiopharmaceuticals, potentially transforming cancer treatment options.
